ACIU Current Deferred Revenue from 2010 to 2024
| ACIU Stock | USD 2.48 0.08 3.33% |
Current Deferred Revenue | First Reported 2015-12-31 | Previous Quarter 338 K | Current Value 138 K | Quarterly Volatility 1.3 M |
Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ACIU main balance sheet or income statement drivers, such as Interest Expense of 167.2 K, Selling General Administrative of 8.3 M or Total Revenue of 20 M, as well as many exotic indicators such as Price To Sales Ratio of 34.98, Dividend Yield of 0.0 or PTB Ratio of 2.11. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
ACIU | Current Deferred Revenue |
Latest AC Immune's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of AC Immune over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. AC Immune's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AC Immune's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
ACIU Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 576,873 | |
| Geometric Mean | 294,791 | |
| Coefficient Of Variation | 189.74 | |
| Mean Deviation | 540,051 | |
| Median | 205,000 | |
| Standard Deviation | 1,094,569 | |
| Sample Variance | 1.2T | |
| Range | 4.4M | |
| R-Value | 0.18 | |
| Mean Square Error | 1.3T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | 42,985 | |
| Total Sum of Squares | 16.8T |
ACIU Current Deferred Revenue History
About AC Immune Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include AC Immune income statement, its balance sheet, and the statement of cash flows. AC Immune investors use historical funamental indicators, such as AC Immune's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although AC Immune investors may use each financial statement separately, they are all related. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AC Immune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on AC Immune Financial Statements. Understanding these patterns can help to make the right decision on long term investment in AC Immune. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 138 K | 131.1 K |
Pair Trading with AC Immune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AC Immune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AC Immune will appreciate offsetting losses from the drop in the long position's value.Moving together with ACIU Stock
| 0.65 | EVOK | Evoke Pharma | PairCorr |
Moving against ACIU Stock
| 0.61 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.53 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.46 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
| 0.44 | IBIO | Ibio Inc | PairCorr |
The ability to find closely correlated positions to AC Immune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AC Immune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AC Immune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AC Immune to buy it.
The correlation of AC Immune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AC Immune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AC Immune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AC Immune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of AC Immune Correlation against competitors. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for ACIU Stock analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is AC Immune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AC Immune. If investors know ACIU will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AC Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share 0.175 | Quarterly Revenue Growth 14.8 K | Return On Assets (0.18) | Return On Equity (0.33) |
The market value of AC Immune is measured differently than its book value, which is the value of ACIU that is recorded on the company's balance sheet. Investors also form their own opinion of AC Immune's value that differs from its market value or its book value, called intrinsic value, which is AC Immune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AC Immune's market value can be influenced by many factors that don't directly affect AC Immune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AC Immune's value and its price as these two are different measures arrived at by different means. Investors typically determine if AC Immune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AC Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.